RxDoctor Payments Data

Jonathan Klahr, MD

Rheumatology · Cedarhurst, NYNPI 1487738936

Payments from drug & device makers

$8,216in general payments, 2019–2025

Across 384 payments — averaging $21.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AbbVie$1K
  • Pfizer$1K
  • UCB, Inc.$1K
  • Lilly USA, LLC$659
  • GSK$348
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$8,13199%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,216 in reported general payments places this provider in the 60th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York

Medicare billing

Part B allowed, 2024
$681,343
Medicare patients
409
Services billed
37,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin27$26,363
JanuviaSitagliptin Phosphate18$26,277
OzempicSemaglutide27$25,664
ProliaDenosumab12$21,123
EliquisApixaban14$7,508
MethotrexateMethotrexate Sodium229$5,219
Colchicine32$3,109
Prednisone271$2,229
Losartan Potassium179$2,183
Irbesartan25$2,072
Raloxifene Hcl64$1,968
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen82$1,412
Dutasteride39$1,336
SynthroidLevothyroxine Sodium14$1,216
Methenamine Hippurate24$1,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$167$26,36327 claims
Novo NordiskOzempic$222$25,66427 claims
AmgenProlia$1,988$21,12312 claims
PfizerEliquis$1,074$7,50814 claims
Scilex Pharmaceuticals Inc.Colchicine$31$3,10932 claims
AbbVieSynthroid$1,208$1,21614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 541 rheumatology providers in New York.

Other rheumatology in Cedarhurst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →